Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry

BACKGROUND: Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma (mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms have been applied to assess outcomes in patients receiving T-cell checkpoint inh...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother Cancer
Päätekijät: Fishman, M., Dutcher, J. P., Clark, J. I., Alva, A., Miletello, G. P., Curti, B., Agarwal, Neeraj, Hauke, R., Mahoney, K. M., Moon, H., Treisman, J., Tykodi, S. S., Daniels, G., Morse, M. A., Wong, M. K. K., Kaufman, H., Gregory, N., McDermott, D. F.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2019
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6437874/
https://ncbi.nlm.nih.gov/pubmed/30917871
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0567-3
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia